JP7759724B2 - エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用 - Google Patents

エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用

Info

Publication number
JP7759724B2
JP7759724B2 JP2020527369A JP2020527369A JP7759724B2 JP 7759724 B2 JP7759724 B2 JP 7759724B2 JP 2020527369 A JP2020527369 A JP 2020527369A JP 2020527369 A JP2020527369 A JP 2020527369A JP 7759724 B2 JP7759724 B2 JP 7759724B2
Authority
JP
Japan
Prior art keywords
ascorbic acid
muscle
medium
egt
differentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020527369A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020004014A5 (enExample
JPWO2020004014A1 (ja
Inventor
邦男 小坂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagase and Co Ltd
Original Assignee
Nagase and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagase and Co Ltd filed Critical Nagase and Co Ltd
Publication of JPWO2020004014A1 publication Critical patent/JPWO2020004014A1/ja
Publication of JPWO2020004014A5 publication Critical patent/JPWO2020004014A5/ja
Priority to JP2023203550A priority Critical patent/JP2024026241A/ja
Priority to JP2025114256A priority patent/JP2025148417A/ja
Application granted granted Critical
Publication of JP7759724B2 publication Critical patent/JP7759724B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pediatric Medicine (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020527369A 2018-06-29 2019-06-11 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用 Active JP7759724B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023203550A JP2024026241A (ja) 2018-06-29 2023-12-01 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用
JP2025114256A JP2025148417A (ja) 2018-06-29 2025-07-07 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018124613 2018-06-29
JP2018124613 2018-06-29
PCT/JP2019/023114 WO2020004014A1 (ja) 2018-06-29 2019-06-11 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023203550A Division JP2024026241A (ja) 2018-06-29 2023-12-01 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用

Publications (3)

Publication Number Publication Date
JPWO2020004014A1 JPWO2020004014A1 (ja) 2021-07-15
JPWO2020004014A5 JPWO2020004014A5 (enExample) 2022-06-17
JP7759724B2 true JP7759724B2 (ja) 2025-10-24

Family

ID=68986429

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020527369A Active JP7759724B2 (ja) 2018-06-29 2019-06-11 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用
JP2023203550A Pending JP2024026241A (ja) 2018-06-29 2023-12-01 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用
JP2025114256A Pending JP2025148417A (ja) 2018-06-29 2025-07-07 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023203550A Pending JP2024026241A (ja) 2018-06-29 2023-12-01 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用
JP2025114256A Pending JP2025148417A (ja) 2018-06-29 2025-07-07 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用

Country Status (6)

Country Link
US (1) US12454678B2 (enExample)
EP (1) EP3816278A4 (enExample)
JP (3) JP7759724B2 (enExample)
CN (1) CN112352046A (enExample)
TW (1) TWI815907B (enExample)
WO (1) WO2020004014A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022230487A1 (enExample) * 2021-04-26 2022-11-03
WO2022242711A1 (en) * 2021-05-20 2022-11-24 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Methods for ameliorating and preventing age‐related muscle degeneration
JP7569818B2 (ja) * 2022-03-11 2024-10-18 キッコーマン株式会社 エルゴチオネインを光に対し安定化させた液体組成物
JPWO2024172003A1 (enExample) * 2023-02-16 2024-08-22
DE102023131771B3 (de) 2023-09-15 2025-02-06 Esspen Gmbh Verfahren und Vorrichtung zur Verarbeitung medizintechnischer Bilddaten im Zusammenhang mit einer Trepanation
WO2026148341A1 (en) * 2025-01-06 2026-07-09 Mironova Labs, Inc ʟ-ERGOTHIONEINE COCRYSTAL AND DERIVATIVES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009167169A (ja) 2007-11-30 2009-07-30 Lvmh Recherche アスコルビン酸−２−グルコシド及びエルゴチオネインを含んでなる化粧組成物
US20150157648A1 (en) 2012-06-26 2015-06-11 Entia Biosciences, Inc. Nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099277A1 (en) 2002-05-20 2003-12-04 Oxis International, Inc. Method of reducing incidence diabetic embryopathy with l-ergothioneine
US20100227307A1 (en) 2007-04-12 2010-09-09 Hausman Marvin S Ergothioneine and/or its derivatives as a cell preservative
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
US20120141611A1 (en) * 2010-12-05 2012-06-07 Oxis International Inc. Methods and compositions using ergothioneine to treat a variety of health related factors
TWI549696B (zh) 2014-09-05 2016-09-21 中國醫藥大學 麥角硫因應用於活化細胞之Ｎｒｆ２訊息途徑之用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009167169A (ja) 2007-11-30 2009-07-30 Lvmh Recherche アスコルビン酸−２−グルコシド及びエルゴチオネインを含んでなる化粧組成物
US20150157648A1 (en) 2012-06-26 2015-06-11 Entia Biosciences, Inc. Nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, Vol. 199, No. 1, pp. 394-402
KAFKAS UNIV VET FAK DERG, 2010, Vol. 16, No. 5, pp. 757-763

Also Published As

Publication number Publication date
JP2025148417A (ja) 2025-10-07
EP3816278A4 (en) 2022-05-04
US20210130787A1 (en) 2021-05-06
US12454678B2 (en) 2025-10-28
CN112352046A (zh) 2021-02-09
TW202015549A (zh) 2020-05-01
TWI815907B (zh) 2023-09-21
WO2020004014A1 (ja) 2020-01-02
JPWO2020004014A1 (ja) 2021-07-15
EP3816278A1 (en) 2021-05-05
JP2024026241A (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
JP2025148417A (ja) エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用
JP2020528085A (ja) 幹細胞から抽出されたエキソソームを有効成分として含む骨粗鬆症の予防または治療用の組成物
TWI830696B (zh) 抑制肌纖維變性用組成物
CN109963574B (zh) 用于预防或治疗肝纤维化的包含脂肪干细胞来源外排体作为活性成分的组合物
US20180104269A1 (en) Composition for suppressing muscular fatty change
US20190038769A1 (en) Micro-rna profiling, compositions, and methods of treating diseases
TWI805560B (zh) 用於使時鐘基因之表現變化的組合物
JP2016202098A (ja) マンネンタケ抽出物を用いた幹細胞の未分化状態維持剤及び増殖促進剤
JP6034107B2 (ja) 幹細胞から褐色脂肪細胞への分化促進剤
EP4544921A1 (en) Composition comprising lactobacillus gasseri for preventing and treating sarcopenia
KR102187681B1 (ko) 히알루론산 나노입자를 함유하는 섬유증의 예방 또는 치료용 약학 조성물
EP3216858B1 (en) Agent for maintaining stem cells in undifferentiated state and agent for promoting growth thereof
US11414663B2 (en) Micro-RNA profiling, compositions, and methods of treating diseases
JP6840376B2 (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
JP7083141B2 (ja) 筋肉量減少又は筋力低下を改善するための組成物及びその利用
JP6587899B2 (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
JP2017108671A (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
JP6154280B2 (ja) 神経幹細胞又は神経前駆細胞の増殖促進剤
JP6615589B2 (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
JP2012136448A (ja) 神経細胞活性化剤
US12606824B2 (en) Micro-RNA profiling, compositions, and methods of treating diseases
JP2014015428A (ja) サテライト細胞分化促進剤
JP2022177817A (ja) ケトン供与体を含む組成物
JP2024164662A (ja) 骨格筋幹細胞の分化促進剤
JP2017086020A (ja) 幹細胞の未分化状態維持剤及び増殖促進剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231207

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240209

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250127

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251014

R150 Certificate of patent or registration of utility model

Ref document number: 7759724

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150